U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C10H15NO
Molecular Weight 165.2322
Optical Activity ( + )
Defined Stereocenters 2 / 2
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of PSEUDOEPHEDRINE

SMILES

CN[C@@H](C)[C@@H](O)C1=CC=CC=C1

InChI

InChIKey=KWGRBVOPPLSCSI-WCBMZHEXSA-N
InChI=1S/C10H15NO/c1-8(11-2)10(12)9-6-4-3-5-7-9/h3-8,10-12H,1-2H3/t8-,10+/m0/s1

HIDE SMILES / InChI

Molecular Formula C10H15NO
Molecular Weight 165.2322
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 2 / 2
E/Z Centers 0
Optical Activity UNSPECIFIED

Description
Curator's Comment: Description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/12373557 | http://www.mayoclinic.org/drugs-supplements/ephedra--ma-huang/background/hrb-20059270 | https://www.sudafed.com/adult-products/congestion/sudafed-24-hour#uses-and-directions | https://www.ncbi.nlm.nih.gov/pubmedhealth/PMHT0011888 | https://www.ncbi.nlm.nih.gov/pubmed/11772135 | https://www.ncbi.nlm.nih.gov/pubmed/10449190 | https://www.ncbi.nlm.nih.gov/pubmed/12954796

Pseudoephedrine is a sympathomimetic drug. Pseudoephedrine acts as an adrenomimetic and inhibitor of monoamine transporters. Ephedra sinica, a species of ephedra (ma huang), contains ephedrine and pseudoephedrine. Ephedra has been found to stimulate the nervous system, increase airflow into the lungs and constrict blood vessels. In combination with caffeine, ephedra appears to cause weight loss. Pseudoephedrine is a decongestant that shrinks blood vessels in the nasal passages. Pseudoephedrine is used to relieve nasal or sinus congestion caused by the common cold, sinusitis, and hay fever and other respiratory allergies.

Originator

Sources: A. Ladenburg, C. Oelschlägel, Ber. 22, 1823 (1889).
Curator's Comment: (+)-threo-isomer of ephedrine, q.v. Isoln from E. vulgaris: A. Ladenburg, C. Oelschlägel, Ber. 22, 1823 (1889). Synthesis: E. Späth, R. Göhring, Monatsh. Chem. 41, 319 (1920). reference retrieved from http://www.drugfuture.com/chemdata/pseudoephedrine.html

Approval Year

TargetsConditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
SUDAFED 24 HOUR

Approved Use

temporarily relieves nasal congestion due to the common cold, hay fever or other upper respiratory allergies; reduces swelling of nasal passages; relieves sinus pressure

Launch Date

7.2429122E11
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
292 ng/mL
120 mg single, oral
dose: 120 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
PSEUDOEPHEDRINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
4346 ng × h/mL
120 mg single, oral
dose: 120 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
PSEUDOEPHEDRINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
6.3 h
120 mg single, oral
dose: 120 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
PSEUDOEPHEDRINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
Doses

Doses

DosePopulationAdverse events​
1500 mg single, oral
Overdose
Dose: 1500 mg
Route: oral
Route: single
Dose: 1500 mg
Sources:
unknown, 16 years
n = 1
Health Status: unknown
Age Group: 16 years
Sex: F
Population Size: 1
Sources:
Other AEs: Rhabdomyolysis, Creatine kinase increased...
Other AEs:
Rhabdomyolysis (1 patient)
Creatine kinase increased (1 patient)
Blood myoglobin increased (1 patient)
Sources:
150 mg 2 times / day multiple, oral
Highest studied dose
Dose: 150 mg, 2 times / day
Route: oral
Route: multiple
Dose: 150 mg, 2 times / day
Sources:
healthy, 24 years
n = 17
Health Status: healthy
Age Group: 24 years
Sex: M
Population Size: 17
Sources:
Other AEs: Tension, Dry mouth...
Other AEs:
Tension (10 patients)
Dry mouth (6 patients)
Tachycardia (9 patients)
Palpitations (10 patients)
Anxiety (13 patients)
Insomnia (12 patients)
Anorexia (7 patients)
Restlessness (10 patients)
Sources:
90 mg 1 times / day multiple, oral
Overdose
Dose: 90 mg, 1 times / day
Route: oral
Route: multiple
Dose: 90 mg, 1 times / day
Sources:
unhealthy, 3 years
n = 1
Health Status: unhealthy
Age Group: 3 years
Sex: M
Population Size: 1
Sources:
Disc. AE: Urinary retention...
AEs leading to
discontinuation/dose reduction:
Urinary retention (acute, 1 patient)
Sources:
30 mg 2 times / day multiple, oral
Dose: 30 mg, 2 times / day
Route: oral
Route: multiple
Dose: 30 mg, 2 times / day
Co-administed with::
acetominophen(500 mg twice daily, oral)
Sources:
unhealthy, 37 years
n = 1
Health Status: unhealthy
Condition: sinusitis
Age Group: 37 years
Sex: F
Population Size: 1
Sources:
Disc. AE: Ischemic colitis, Abdominal pain...
AEs leading to
discontinuation/dose reduction:
Ischemic colitis (1 patient)
Abdominal pain (acute, 1 patient)
Sources:
720 mg 1 times / day multiple, oral
Highest studied dose
Dose: 720 mg, 1 times / day
Route: oral
Route: multiple
Dose: 720 mg, 1 times / day
Sources:
unhealthy, 38.8 years
n = 38
Health Status: unhealthy
Age Group: 38.8 years
Sex: M+F
Population Size: 38
Sources:
30 mg 3 times / day multiple, oral
Dose: 30 mg, 3 times / day
Route: oral
Route: multiple
Dose: 30 mg, 3 times / day
Sources:
unhealthy, 44 years
n = 1
Health Status: unhealthy
Condition: upper airway infection
Age Group: 44 years
Sex: F
Population Size: 1
Sources:
Disc. AE: Ischemic colitis, Abdominal pain...
AEs leading to
discontinuation/dose reduction:
Ischemic colitis (1 patient)
Abdominal pain (acute, 1 patient)
Sources:
120 mg 1 times / day multiple, oral
Dose: 120 mg, 1 times / day
Route: oral
Route: multiple
Dose: 120 mg, 1 times / day
Sources:
unhealthy, 46 years
n = 1
Health Status: unhealthy
Condition: chronic sinusitis | allergic rhinitis
Age Group: 46 years
Sex: F
Population Size: 1
Sources:
Disc. AE: Ischemic colitis, Abdominal pain...
AEs leading to
discontinuation/dose reduction:
Ischemic colitis (1 patient)
Abdominal pain (acute, 1 patient)
Sources:
30 mg 2 times / day multiple, oral
Dose: 30 mg, 2 times / day
Route: oral
Route: multiple
Dose: 30 mg, 2 times / day
Co-administed with::
acetominophen(500 mg twice daily, oral)
chlorpheniramine maleate(2 mg; twice daily, oral)
Sources:
unhealthy, 50 years
n = 1
Health Status: unhealthy
Condition: rhinitis
Age Group: 50 years
Sex: F
Population Size: 1
Sources:
Disc. AE: Ischemic colitis, Abdominal pain...
AEs leading to
discontinuation/dose reduction:
Ischemic colitis (1 patient)
Abdominal pain (acute, 1 patient)
Sources:
720 mg single, oral
Overdose
Dose: 720 mg
Route: oral
Route: single
Dose: 720 mg
Sources:
unhealthy, 87 years
n = 1
Health Status: unhealthy
Age Group: 87 years
Sex: M
Population Size: 1
Sources:
Other AEs: Hypertension...
Other AEs:
Hypertension (1 patient)
Sources:
AEs

AEs

AESignificanceDosePopulation
Blood myoglobin increased 1 patient
1500 mg single, oral
Overdose
Dose: 1500 mg
Route: oral
Route: single
Dose: 1500 mg
Sources:
unknown, 16 years
n = 1
Health Status: unknown
Age Group: 16 years
Sex: F
Population Size: 1
Sources:
Creatine kinase increased 1 patient
1500 mg single, oral
Overdose
Dose: 1500 mg
Route: oral
Route: single
Dose: 1500 mg
Sources:
unknown, 16 years
n = 1
Health Status: unknown
Age Group: 16 years
Sex: F
Population Size: 1
Sources:
Rhabdomyolysis 1 patient
1500 mg single, oral
Overdose
Dose: 1500 mg
Route: oral
Route: single
Dose: 1500 mg
Sources:
unknown, 16 years
n = 1
Health Status: unknown
Age Group: 16 years
Sex: F
Population Size: 1
Sources:
Palpitations 10 patients
150 mg 2 times / day multiple, oral
Highest studied dose
Dose: 150 mg, 2 times / day
Route: oral
Route: multiple
Dose: 150 mg, 2 times / day
Sources:
healthy, 24 years
n = 17
Health Status: healthy
Age Group: 24 years
Sex: M
Population Size: 17
Sources:
Restlessness 10 patients
150 mg 2 times / day multiple, oral
Highest studied dose
Dose: 150 mg, 2 times / day
Route: oral
Route: multiple
Dose: 150 mg, 2 times / day
Sources:
healthy, 24 years
n = 17
Health Status: healthy
Age Group: 24 years
Sex: M
Population Size: 17
Sources:
Tension 10 patients
150 mg 2 times / day multiple, oral
Highest studied dose
Dose: 150 mg, 2 times / day
Route: oral
Route: multiple
Dose: 150 mg, 2 times / day
Sources:
healthy, 24 years
n = 17
Health Status: healthy
Age Group: 24 years
Sex: M
Population Size: 17
Sources:
Insomnia 12 patients
150 mg 2 times / day multiple, oral
Highest studied dose
Dose: 150 mg, 2 times / day
Route: oral
Route: multiple
Dose: 150 mg, 2 times / day
Sources:
healthy, 24 years
n = 17
Health Status: healthy
Age Group: 24 years
Sex: M
Population Size: 17
Sources:
Anxiety 13 patients
150 mg 2 times / day multiple, oral
Highest studied dose
Dose: 150 mg, 2 times / day
Route: oral
Route: multiple
Dose: 150 mg, 2 times / day
Sources:
healthy, 24 years
n = 17
Health Status: healthy
Age Group: 24 years
Sex: M
Population Size: 17
Sources:
Dry mouth 6 patients
150 mg 2 times / day multiple, oral
Highest studied dose
Dose: 150 mg, 2 times / day
Route: oral
Route: multiple
Dose: 150 mg, 2 times / day
Sources:
healthy, 24 years
n = 17
Health Status: healthy
Age Group: 24 years
Sex: M
Population Size: 17
Sources:
Anorexia 7 patients
150 mg 2 times / day multiple, oral
Highest studied dose
Dose: 150 mg, 2 times / day
Route: oral
Route: multiple
Dose: 150 mg, 2 times / day
Sources:
healthy, 24 years
n = 17
Health Status: healthy
Age Group: 24 years
Sex: M
Population Size: 17
Sources:
Tachycardia 9 patients
150 mg 2 times / day multiple, oral
Highest studied dose
Dose: 150 mg, 2 times / day
Route: oral
Route: multiple
Dose: 150 mg, 2 times / day
Sources:
healthy, 24 years
n = 17
Health Status: healthy
Age Group: 24 years
Sex: M
Population Size: 17
Sources:
Urinary retention acute, 1 patient
Disc. AE
90 mg 1 times / day multiple, oral
Overdose
Dose: 90 mg, 1 times / day
Route: oral
Route: multiple
Dose: 90 mg, 1 times / day
Sources:
unhealthy, 3 years
n = 1
Health Status: unhealthy
Age Group: 3 years
Sex: M
Population Size: 1
Sources:
Ischemic colitis 1 patient
Disc. AE
30 mg 2 times / day multiple, oral
Dose: 30 mg, 2 times / day
Route: oral
Route: multiple
Dose: 30 mg, 2 times / day
Co-administed with::
acetominophen(500 mg twice daily, oral)
Sources:
unhealthy, 37 years
n = 1
Health Status: unhealthy
Condition: sinusitis
Age Group: 37 years
Sex: F
Population Size: 1
Sources:
Abdominal pain acute, 1 patient
Disc. AE
30 mg 2 times / day multiple, oral
Dose: 30 mg, 2 times / day
Route: oral
Route: multiple
Dose: 30 mg, 2 times / day
Co-administed with::
acetominophen(500 mg twice daily, oral)
Sources:
unhealthy, 37 years
n = 1
Health Status: unhealthy
Condition: sinusitis
Age Group: 37 years
Sex: F
Population Size: 1
Sources:
Ischemic colitis 1 patient
Disc. AE
30 mg 3 times / day multiple, oral
Dose: 30 mg, 3 times / day
Route: oral
Route: multiple
Dose: 30 mg, 3 times / day
Sources:
unhealthy, 44 years
n = 1
Health Status: unhealthy
Condition: upper airway infection
Age Group: 44 years
Sex: F
Population Size: 1
Sources:
Abdominal pain acute, 1 patient
Disc. AE
30 mg 3 times / day multiple, oral
Dose: 30 mg, 3 times / day
Route: oral
Route: multiple
Dose: 30 mg, 3 times / day
Sources:
unhealthy, 44 years
n = 1
Health Status: unhealthy
Condition: upper airway infection
Age Group: 44 years
Sex: F
Population Size: 1
Sources:
Ischemic colitis 1 patient
Disc. AE
120 mg 1 times / day multiple, oral
Dose: 120 mg, 1 times / day
Route: oral
Route: multiple
Dose: 120 mg, 1 times / day
Sources:
unhealthy, 46 years
n = 1
Health Status: unhealthy
Condition: chronic sinusitis | allergic rhinitis
Age Group: 46 years
Sex: F
Population Size: 1
Sources:
Abdominal pain acute, 1 patient
Disc. AE
120 mg 1 times / day multiple, oral
Dose: 120 mg, 1 times / day
Route: oral
Route: multiple
Dose: 120 mg, 1 times / day
Sources:
unhealthy, 46 years
n = 1
Health Status: unhealthy
Condition: chronic sinusitis | allergic rhinitis
Age Group: 46 years
Sex: F
Population Size: 1
Sources:
Ischemic colitis 1 patient
Disc. AE
30 mg 2 times / day multiple, oral
Dose: 30 mg, 2 times / day
Route: oral
Route: multiple
Dose: 30 mg, 2 times / day
Co-administed with::
acetominophen(500 mg twice daily, oral)
chlorpheniramine maleate(2 mg; twice daily, oral)
Sources:
unhealthy, 50 years
n = 1
Health Status: unhealthy
Condition: rhinitis
Age Group: 50 years
Sex: F
Population Size: 1
Sources:
Abdominal pain acute, 1 patient
Disc. AE
30 mg 2 times / day multiple, oral
Dose: 30 mg, 2 times / day
Route: oral
Route: multiple
Dose: 30 mg, 2 times / day
Co-administed with::
acetominophen(500 mg twice daily, oral)
chlorpheniramine maleate(2 mg; twice daily, oral)
Sources:
unhealthy, 50 years
n = 1
Health Status: unhealthy
Condition: rhinitis
Age Group: 50 years
Sex: F
Population Size: 1
Sources:
Hypertension 1 patient
720 mg single, oral
Overdose
Dose: 720 mg
Route: oral
Route: single
Dose: 720 mg
Sources:
unhealthy, 87 years
n = 1
Health Status: unhealthy
Age Group: 87 years
Sex: M
Population Size: 1
Sources:
PubMed

PubMed

TitleDatePubMed
Recurrent ischaemic colitis associated with pseudoephedrine use.
2001 Apr
Mass spectrometric quantitation of chiral drugs by the kinetic method.
2001 Apr 15
Study on the chiral recognition of the enantiomers of ephedrine derivatives with neutral and sulfated heptakis(2,3-O-diacetyl)-beta-cyclodextrins using capillary electrophoresis, UV, nuclear magnetic resonance spectroscopy and mass spectrometry.
2001 Apr 20
Hypokalemic metabolic acidosis attributed to cough mixture abuse.
2001 Aug
A fast and efficient determination of amines and preservatives in cough and cold liquid and suspension formulations using a single isocratic ion-pairing high performance [correction of power] liquid chromatography method.
2001 Aug
Aziridine ring-opening reactions with chiral enolates. Stereocontrolled synthesis of 5-substituted-3-methyl-pyrrolidin-2-ones.
2001 Aug 24
Effect of organic cations on the renal tubular secretion of pseudoephedrine in the rat.
2001 Jan-Feb
Human islet transplantation network for the treatment of Type I diabetes: first data from the Swiss-French GRAGIL consortium (1999-2000). Groupe de Recherche Rhin Rhĵne Alpes Genève pour la transplantation d'Ilots de Langerhans.
2001 Jul
New observations on the secondary chemistry of world Ephedra (Ephedraceae).
2001 Jul
Cold-syrup induced movement disorder.
2001 Jun
[Cost effectiveness of GM-CSF in the treatment of acute myeloblastic leukemia in aged patients: protocol of GOELAM Sa3].
2001 Mar-Apr
[Separation and determination of pseudoephedrine in bufferin cold tablet by capillary electrophoresis with hydropropyl-beta-cyclodextrin as chiral selective reagent].
2001 Nov
Biotransformation of benzaldehyde into (R)-phenylacetylcarbinol by filamentous fungi or their extracts.
2001 Oct
Relationship between expansion of the CAG repeat in exon 1 of the androgen receptor gene and idiopathic male infertility.
2001 Oct
Kinetic spectrophotometric methods for the quantitation of triprolidine in bulk and in drug formulations.
2001 Sep
Rapid chiral on-chip separation with simplified amperometric detection.
2001 Sep 14
Evaluation of a pseudoephedrine linker for asymmetric alkylations on solid phase.
2002 Dec 26
Linezolid: its role in the treatment of gram-positive, drug-resistant bacterial infections.
2002 Feb 15
Pseudoephedrine causing mania-like symptoms.
2002 Feb 22
Immediate hypersensitivity due to pseudoephedrine.
2002 Jan
Modifying the bitterness of selected oral pharmaceuticals with cation and anion series of salts.
2002 Jul
Onset of action, efficacy, and safety of fexofenadine 60 mg/pseudoephedrine 120 mg versus placebo in the Atlanta allergen exposure unit.
2002 Jul
Rapid simultaneous determination of amphetamine, methamphetamine, 3,4-methylenedioxyamphetamine, 3,4-methylenedioxymethamphetamine, and 3,4-methylenedioxyethylamphetamine in urine by solid-phase extraction and GC-MS: a method optimized for high-volume laboratories.
2002 Jul-Aug
A comparative study of the side effects between pseudoephedrine in Loratadine plus Pseudoephedrine Sulfate Repetabs Tables and loratadine + pseudoephedrine tablet in treatment of allergic rhinitis in Thai patients.
2002 Jun
Oral medications.
2002 Mar
Implementation of the Comprehensive Methamphetamine Control Act of 1996; regulation of pseudoephedrine, phenylpropanolamine, and combination ephedrine drug products and reports of certain transactions to nonregulated persons. Final rule.
2002 Mar 28
Pigmented purpuric dermatosis due to pseudoephedrine.
2002 May
Pseudoephedrine as a chiral auxiliary for asymmetric Michael reactions: synthesis of 3-aryl-delta-lactones.
2002 May 30
A moderate dose of pseudoephedrine does not alter muscle contraction strength or anaerobic power.
2002 Nov
Quantitative and structural determination of pseudoephedrine sulfate and its related compounds in pharmaceutical preparations using high-performance liquid chromatography.
2002 Nov 7
[Blood supply of the lips].
2002 Oct
Pharmacokinetic interaction study of a fixed combination of 500 mg acetylsalicylic acid/30 mg pseudoephedrine versus each of the single active ingredients in healthy male volunteers.
2003
Baboon syndrome due to pseudoephedrine.
2003 Apr
Sensitive determination of ephedrine and pseudoephedrine by capillary electrophoresis with laser-induced fluorescence detection.
2003 Apr
Controlled porosity osmotic pump-based controlled release systems of pseudoephedrine. I. Cellulose acetate as a semipermeable membrane.
2003 Apr 14
Stroke associated with sympathomimetics contained in over-the-counter cough and cold drugs.
2003 Jul
Development and validation of a capillary zone electrophoresis method for the determination of ephedrine and related compounds in urine without extraction.
2003 Jul 5
[Tobacco: knowledge, reasoning and opinion of high school students in Doubs. Reflections on prevention].
2003 Mar
Safety of selegiline with cold medications.
2003 Mar
Adrenaline given outside the context of life threatening allergic reactions.
2003 Mar 15
Spectrophotometric determination of binary mixtures of pseudoephedrine with some histamine H1-receptor antagonists using derivative ratio spectrum method.
2003 Mar 26
Patents

Sample Use Guides

SUDAFED® 24 HOUR TABLET, EXTENDED RELEASE; ORAL (PSEUDOEPHEDRINE HYDROCHLORIDE) 240MG adults and children 12 years and older: a tablet with water every 24 hours children under 12 years: do not use this product in children under 12 years of age
Route of Administration: Oral
In Vitro Use Guide
Curator's Comment: Pseudoephedrine inhibits interleukin-2 (IL-2) and tumor necrosis factor (TNF) alpha-gene transcription in stimulated Jurkat cells, a human T-cell leukemia cell line.
Unknown
Substance Class Chemical
Created
by admin
on Fri Dec 15 15:21:38 UTC 2023
Edited
by admin
on Fri Dec 15 15:21:38 UTC 2023
Record UNII
7CUC9DDI9F
Record Status Validated (UNII)
Record Version
  • Download
Related Record Type
Name Type Language
PSEUDOEPHEDRINE
HSDB   INN   MART.   MI   VANDF   WHO-DD  
INN  
Official Name English
(1S,2S)-(+)-PSEUDOEPHEDRINE
Common Name English
(.ALPHA.S)-.ALPHA.-((1R)-1-(METHYLAMINO)ETHYL)BENZENEMETHANOL
Systematic Name English
(+)-(1S,2S)-PSEUDOEPHEDRINE
Common Name English
PSEUDOEPHEDRINE [VANDF]
Common Name English
EPHEDRINE HYDROCHLORIDE IMPURITY B [EP IMPURITY]
Common Name English
ACUNASO
Brand Name English
1-(S),2-(R)-ERYTHRO-(+)-EPHEDRINE
Common Name English
BENZENEMETHANOL, .ALPHA.-((1S)-1-(METHYLAMINO)ETHYL)-, (.ALPHA.S)-
Systematic Name English
pseudoephedrine [INN]
Common Name English
PSEUDOEPHEDRINE [HSDB]
Common Name English
(+)-THREO-EPHEDRINE
Common Name English
PSEUDOEPHEDRINE [MI]
Common Name English
PSEUDOEPHEDRINE [MART.]
Common Name English
Pseudoephedrine [WHO-DD]
Common Name English
ISOEPHEDRINE, D-
Common Name English
BENZENEMETHANOL, .ALPHA.-(1-(METHYLAMINO)ETHYL)-, (S-(R*,R*))-
Systematic Name English
(+)-PSEUDOEPHEDRINE
Common Name English
PSEUDOEPHEDRINE, (+)-
Common Name English
NEODURASINA
Brand Name English
Classification Tree Code System Code
WHO-VATC QR01BA02
Created by admin on Fri Dec 15 15:21:38 UTC 2023 , Edited by admin on Fri Dec 15 15:21:38 UTC 2023
CFR 21 CFR 119.1
Created by admin on Fri Dec 15 15:21:38 UTC 2023 , Edited by admin on Fri Dec 15 15:21:38 UTC 2023
WHO-VATC QR01BA52
Created by admin on Fri Dec 15 15:21:38 UTC 2023 , Edited by admin on Fri Dec 15 15:21:38 UTC 2023
NDF-RT N0000175552
Created by admin on Fri Dec 15 15:21:38 UTC 2023 , Edited by admin on Fri Dec 15 15:21:38 UTC 2023
NCI_THESAURUS C29709
Created by admin on Fri Dec 15 15:21:38 UTC 2023 , Edited by admin on Fri Dec 15 15:21:38 UTC 2023
CFR 21 CFR 1314.20
Created by admin on Fri Dec 15 15:21:38 UTC 2023 , Edited by admin on Fri Dec 15 15:21:38 UTC 2023
DEA NO. 8525
Created by admin on Fri Dec 15 15:21:38 UTC 2023 , Edited by admin on Fri Dec 15 15:21:38 UTC 2023
WHO-ATC R01BA02
Created by admin on Fri Dec 15 15:21:38 UTC 2023 , Edited by admin on Fri Dec 15 15:21:38 UTC 2023
LIVERTOX 813
Created by admin on Fri Dec 15 15:21:38 UTC 2023 , Edited by admin on Fri Dec 15 15:21:38 UTC 2023
NDF-RT N0000000209
Created by admin on Fri Dec 15 15:21:38 UTC 2023 , Edited by admin on Fri Dec 15 15:21:38 UTC 2023
WHO-ATC R01BA52
Created by admin on Fri Dec 15 15:21:38 UTC 2023 , Edited by admin on Fri Dec 15 15:21:38 UTC 2023
CFR 21 CFR 1315.13
Created by admin on Fri Dec 15 15:21:38 UTC 2023 , Edited by admin on Fri Dec 15 15:21:38 UTC 2023
Code System Code Type Description
CAS
90-82-4
Created by admin on Fri Dec 15 15:21:38 UTC 2023 , Edited by admin on Fri Dec 15 15:21:38 UTC 2023
PRIMARY
IUPHAR
7286
Created by admin on Fri Dec 15 15:21:38 UTC 2023 , Edited by admin on Fri Dec 15 15:21:38 UTC 2023
PRIMARY
EPA CompTox
DTXSID0023537
Created by admin on Fri Dec 15 15:21:38 UTC 2023 , Edited by admin on Fri Dec 15 15:21:38 UTC 2023
PRIMARY
EVMPD
SUB10157MIG
Created by admin on Fri Dec 15 15:21:38 UTC 2023 , Edited by admin on Fri Dec 15 15:21:38 UTC 2023
PRIMARY
DRUG BANK
DB00852
Created by admin on Fri Dec 15 15:21:38 UTC 2023 , Edited by admin on Fri Dec 15 15:21:38 UTC 2023
PRIMARY
RXCUI
8896
Created by admin on Fri Dec 15 15:21:38 UTC 2023 , Edited by admin on Fri Dec 15 15:21:38 UTC 2023
PRIMARY RxNorm
FDA UNII
7CUC9DDI9F
Created by admin on Fri Dec 15 15:21:38 UTC 2023 , Edited by admin on Fri Dec 15 15:21:38 UTC 2023
PRIMARY
INN
1061
Created by admin on Fri Dec 15 15:21:38 UTC 2023 , Edited by admin on Fri Dec 15 15:21:38 UTC 2023
PRIMARY
MESH
D054199
Created by admin on Fri Dec 15 15:21:38 UTC 2023 , Edited by admin on Fri Dec 15 15:21:38 UTC 2023
PRIMARY
LACTMED
Pseudoephedrine
Created by admin on Fri Dec 15 15:21:38 UTC 2023 , Edited by admin on Fri Dec 15 15:21:38 UTC 2023
PRIMARY
RXCUI
407885
Created by admin on Fri Dec 15 15:21:38 UTC 2023 , Edited by admin on Fri Dec 15 15:21:38 UTC 2023
ALTERNATIVE
NCI_THESAURUS
C61914
Created by admin on Fri Dec 15 15:21:38 UTC 2023 , Edited by admin on Fri Dec 15 15:21:38 UTC 2023
PRIMARY
MERCK INDEX
m9294
Created by admin on Fri Dec 15 15:21:38 UTC 2023 , Edited by admin on Fri Dec 15 15:21:38 UTC 2023
PRIMARY Merck Index
ECHA (EC/EINECS)
202-018-6
Created by admin on Fri Dec 15 15:21:38 UTC 2023 , Edited by admin on Fri Dec 15 15:21:38 UTC 2023
PRIMARY
CHEBI
51209
Created by admin on Fri Dec 15 15:21:38 UTC 2023 , Edited by admin on Fri Dec 15 15:21:38 UTC 2023
PRIMARY
ChEMBL
CHEMBL1590
Created by admin on Fri Dec 15 15:21:38 UTC 2023 , Edited by admin on Fri Dec 15 15:21:38 UTC 2023
PRIMARY
SMS_ID
100000085477
Created by admin on Fri Dec 15 15:21:38 UTC 2023 , Edited by admin on Fri Dec 15 15:21:38 UTC 2023
PRIMARY
WIKIPEDIA
PSEUDOEPHEDRINE
Created by admin on Fri Dec 15 15:21:38 UTC 2023 , Edited by admin on Fri Dec 15 15:21:38 UTC 2023
PRIMARY
HSDB
3177
Created by admin on Fri Dec 15 15:21:38 UTC 2023 , Edited by admin on Fri Dec 15 15:21:38 UTC 2023
PRIMARY
PUBCHEM
7028
Created by admin on Fri Dec 15 15:21:38 UTC 2023 , Edited by admin on Fri Dec 15 15:21:38 UTC 2023
PRIMARY
DAILYMED
7CUC9DDI9F
Created by admin on Fri Dec 15 15:21:38 UTC 2023 , Edited by admin on Fri Dec 15 15:21:38 UTC 2023
PRIMARY
DRUG CENTRAL
2326
Created by admin on Fri Dec 15 15:21:38 UTC 2023 , Edited by admin on Fri Dec 15 15:21:38 UTC 2023
PRIMARY
Related Record Type Details
SALT/SOLVATE -> PARENT
TARGET -> AGONIST
SALT/SOLVATE -> PARENT
TARGET -> INHIBITOR
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
TARGET -> INHIBITOR
TARGET -> INHIBITOR
DIASTEREOISOMER -> DIASTEREOISOMER
SUB_CONCEPT->SUBSTANCE
Related Record Type Details
METABOLITE -> PARENT
MAJOR
Related Record Type Details
PARENT -> IMPURITY
PARENT -> IMPURITY
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
Related Record Type Details
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
Biological Half-life PHARMACOKINETIC